Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $21.1429.

Several equities research analysts have weighed in on RCUS shares. Wall Street Zen upgraded shares of Arcus Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Wells Fargo & Company dropped their price objective on Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Saturday, September 27th.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,831 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $13.00, for a total transaction of $36,803.00. Following the sale, the chief accounting officer directly owned 27,363 shares in the company, valued at approximately $355,719. This trade represents a 9.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in RCUS. GAMMA Investing LLC boosted its stake in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Arcus Biosciences by 8.0% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after buying an additional 1,294 shares during the period. Parallel Advisors LLC grew its holdings in shares of Arcus Biosciences by 1.6% during the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock worth $716,000 after buying an additional 1,422 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after buying an additional 1,796 shares in the last quarter. Finally, Maryland State Retirement & Pension System raised its position in Arcus Biosciences by 10.9% in the 1st quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock valued at $159,000 after buying an additional 1,986 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Trading Down 0.2%

NYSE:RCUS opened at $13.35 on Wednesday. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -4.21 and a beta of 0.77. Arcus Biosciences has a 1-year low of $6.50 and a 1-year high of $18.98. The business’s 50-day moving average price is $11.03 and its two-hundred day moving average price is $9.47. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.18.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. The company had revenue of $160.00 million during the quarter, compared to analysts’ expectations of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.Arcus Biosciences’s revenue was up 310.3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.02) EPS. On average, equities analysts expect that Arcus Biosciences will post -3.15 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.